A promising breakthrough against antibiotic resistance

Antimicrobial resistance (AMR) is a major global health threat, causing nearly 5 million deaths in 2019. Given the urgency, identifying new treatments is more critical than ever. In this context, BWC0977, a bacterial topoisomerase inhibitor, emerges as an innovative therapeutic candidate effective against pathogens resistant to conventional treatments. With a broad spectrum of activity and demonstrated tolerability in clinical trials, it offers concrete solutions for critical infections.